Brief: Hepion Pharmaceuticals Announces FDA Clearance Of Ind Application For CRV431 In The Treatment Of Liver Cancer
21/12/2021 13:06
Dec 21 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND
APPLICATION FOR CRV431 IN THE TREATMENT OF LIVER CANCER
* HEPION PHARMACEUTICALS - IND CLEARANCE ALLOWS CRV431 TO
MOVE
DIRECTLY INTO PHASE 2 FOR HEPATOCELLULAR CARCINOMA TREATMENT
* HEPION PHARMACEUTICALS - NEW IND EXPANDS LIVER DISEASE
PIPELINE
FOR CRV431
* HEPION PHARMACEUTICALS - NEW IND PROVIDES FOR
COMPLEMENTARY
THERAPEUTIC APPROACH OF TREATING NASH AND LIVER CANCER WITH
SINGLE ONCE-A-DAY ORAL AGENT
* HEPION PHARMACEUTICALS - LARGER PHASE 2B NASH STUDY OF
OVER 300
SUBJECTS WITH PAIRED LIVER BIOPSIES, CALLED 'ASCEND-NASH',
EXPECTED TO INITIATE 2022
* HEPION PHARMACEUTICALS INC - ASCEND-NASH WILL EVALUATE
CRV431'S
EFFECTS ON HISTOLOGIC ENDPOINTS OF LIVER STEATOSIS AND FIBROSIS
OVER 12 MONTHS DOSING
Source text for Eikon: ID:nGNX260ZQ5
Further company coverage: HEPA.O
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement